GENEURO
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The company is primarily focused on nervous system diseases such as multiple sclerosis and schizophrenia. Its products include GNbAC1, a therapeutic monoclonal antibody for the treatment of multiple sclerosis. It also develops diagnostic tests to dose the multiple sclerosis-associated retrovirus-ENV proteins in patients.GeNeuro was founded in 2006 and is based in Plan-Les-Ouates, Switzerland.
GENEURO
Social Links:
Industry:
Biotechnology Health Care Therapeutics
Founded:
2006-01-01
Address:
Geneva, Geneve, Switzerland
Country:
Switzerland
Website Url:
http://www.geneuro.com
Total Employee:
11+
Status:
Active
Contact:
+41227945085
Email Addresses:
[email protected]
Total Funding:
41.77 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF Google Font API Google Analytics Content Delivery Network Google Universal Analytics Apache Euro PHP
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Institut Merieux
Institut Merieux investment in Post-IPO Equity - GeNeuro
Invesco
Invesco investment in Post-IPO Equity - GeNeuro
Federal Office of Public Health (FOPH) Switzerland
Federal Office of Public Health (FOPH) Switzerland investment in Grant - GeNeuro
Eclosion SA
Eclosion SA investment in Venture Round - GeNeuro
Key Employee Changes
| Date | New article |
|---|---|
| 2020-04-21 | GeNeuro Appoints MS Clinical Development Expert Dr. David Leppert as Chief Medical Officer |
Official Site Inspections
http://www.geneuro.com Semrush global rank: 7.53 M Semrush visits lastest month: 462
- Host name: h2web367.infomaniak.ch
- IP address: 83.166.133.74
- Location: Switzerland
- Latitude: 47.1449
- Longitude: 8.1551
- Timezone: Europe/Zurich
More informations about "GeNeuro"
Geneuro
[email protected]; X-twitter Linkedin Youtube. Results of the GNC-501 study. June 2024 ...See details»
Company Overview - Geneuro
GeNeuro has also entered into a partnership with the National Institute of Neurological Disorders and Stroke (NINDS, part of the NIH), as NINDS evidenced the potential role of another HERV …See details»
GeNeuro - Crunchbase Company Profile & Funding
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The …See details»
GeNeuro SA - LinkedIn
GeNeuro is a biotechnology company developing innovative treatments against inflammatory and neurodegenerative disorders associated with Human Endogenous Retroviruses (HERVs).See details»
Pipeline Overview - GeNeuro
GeNeuro’s most advanced therapeutic candidate, temelimab, is a humanized monoclonal antibody that neutralizes a pathogenic protein of the HERV-W (W-ENV) family identified as a …See details»
Company History – Geneuro
GeNeuro launches a formal preclinical effort aiming to obtain an IND by mid-2020. Signing of a financing agreement with GNEH SAS, a subsidiary of Institut Mérieux, to establish a €7.5 …See details»
GeNeuro SA – Swiss Biotech
GeNeuro's temelimab, a humanized monoclonal antibody targeting HERV-W Env, has shown a coherent impact across all key markers associated with disease progression in a 200-patient …See details»
GeNeuro - Products, Competitors, Financials, Employees, …
GeNeuro operates as a biotechnology company. Use the CB Insights Platform to explore GeNeuro's full profile. GeNeuro - Products, Competitors, Financials, Employees, …See details»
GeNeuro Company Profile - Office Locations, Competitors ... - Craft
Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other diseases …See details»
GeNeuro - Contacts, Employees, Board Members, Advisors & Alumni
Organization. GeNeuro . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 5. Number of Board …See details»
GeNeuro - Products, Competitors, Financials, Employees, …
GeNeuro is a biotechnology company that develops therapies for autoimmune diseases. Use the CB Insights Platform to explore GeNeuro's full profile. ... Meanwhile, CureVac said its …See details»
GeNeuro (EPA:GNRO) Company Profile & Description - Stock …
Apr 11, 2025 GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. The company’s lead therapeutic …See details»
Geneuro - VentureRadar
GeNeuro is committed to stopping neurodegenerative and autoimmune diseases through targeting causal factors of these pathologies by leveraging the emerging biology of human …See details»
GeNeuro - Funding, Financials, Valuation & Investors - Crunchbase
How much funding has this organization raised over time? Show . Announced Date . Transaction Name . Number of Investors . Money Raised . Lead Investors . Access exclusive financial …See details»
Profil de l'entreprise - GeNeuro
GeNeuro a lancé un programme de développement préclinique d’un nouvel anticorps ciblant HERV-K Env. La compréhension croissante de la biologie des HERV dans de nombreux …See details»
☑️GeNeuro SA — Consulting Organization from
GeNeuro SA — Consulting Organization from Switzerland, has experience with Horizon Europe (2021 - 2027), it`s involved in Health, Laboratory & Measurement, Research, Science & …See details»
GeNeuro SA | European Clinical Trials Information Network
GeNeuro SA is a Swiss biotechnology company that specializes in developing innovative treatments for neurological and au. Menu. Search for Clinical Trials. Autoimmunity. Cancers. …See details»
Geneuro SA, GEM:BER profile - FT.com - Financial Times
Apr 4, 2025 Geneuro SA is a Switzerland-based clinical stage pharmaceutical company that develops treatments for autoimmune diseases, including multiple sclerosis (MS) and other …See details»
News & Press - Geneuro
Dec 6, 2024 Geneva, Switzerland, 30 September 2024 – 7:00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – G NRO), a biopharmaceutical company developing new treatments …See details»
DNA organization offers clues for advancing stem cell therapy
4 days ago Scientists at the University of California, Riverside, have discovered how adult stem cells retain their regenerative power. The researchers demonstrate in a paper published in the …See details»